Table 1 Association of EFGR expression with clinicopathologic features of triple negative breast cancer
| Â | n(%) | P-Value | ||||
|---|---|---|---|---|---|---|
No Expression (n=122) | Low Expression (n=24) | High Expression (n=4) | Total (n=150) | |||
Age Group | ≤30 years | 5 (4.1) | 0 (0) | 0 (0) | 5 (3.3) | 0.264 |
31-50 years | 69 (56.6) | 11 (45.8) | 4 (100) | 84 (56) | ||
>50 years | 48 (39.3) | 13 (54.2) | 0 (0) | 61 (40.7) | ||
Ki67 Index | ≤15% | 15 (12.3) | 2 (8.3) | 0 (0) | 17 (11.3) | 0.646 |
15-24% | 6 (4.9) | 2 (8.3) | 0 (0) | 8 (5.3) | ||
25-44% | 35 (28.7) | 7 (29.2) | 3 (75) | 45 (30) | ||
>44% | 66 (54.1) | 13 (54.2) | 1 (25) | 80 (53.3) | ||
Tumor Size/T stage | T1(≤2 cm) | 22 (18) | 4 (16.7) | 0 (0) | 26 (17.3) | 0.954 |
T2(2.1-4 cm) | 64 (52.5) | 13 (54.2) | 2 (50) | 79 (52.7) | ||
T3(>4 cm) | 36 (29.5) | 7 (29.2) | 2 (50) | 45 (30) | ||
Nodal Stage | N0 | 74 (60.7) | 12 (50) | 2 (50) | 88 (58.7) | 0.539 |
N1 | 24 (19.7) | 4 (16.7) | 2 (50) | 30 (20) | ||
N2 | 10 (8.2) | 3 (12.5) | 0 (0) | 13 (8.7) | ||
N3 | 14 (11.5) | 5 (20.8) | 0 (0) | 19 (12.7) | ||
Tumor grade | Grade I | 1 (0.8) | 0 (0) | 0 (0) | 1 (0.7) | 1.000 |
Grade II | 16 (13.1) | 3 (12.5) | 0 (0) | 19 (12.7) | ||
Grade III | 105 (86.1) | 21 (87.5) | 4 (100) | 130 (86.7) | ||
Histological subtypes | IDC | 106 (86.9) | 18 (75) | 3 (75) | 127 (84.7) | 0.353 |
Papillary | 4 (3.3) | 2 (8.3) | 0 (0) | 6 (4) | ||
Medullary | 1 (0.8) | 0 (0) | 0 (0) | 1 (0.7) | ||
Metaplastic | 9 (7.4) | 4 (16.7) | 1 (25) | 14 (9.3) | ||
Mixed | 2 (1.6) | 0 (0) | 0 (0) | 2 (1.3) | ||
Lymphovascular Invasion | Present | 27 (22.1) | 8 (33.3) | 1 (25) | 36 (24) | 0.470 |
Absent | 95 (77.9) | 16 (66.7) | 3 (75) | 114 (76) | ||
Triple negative phenotypes | Basal | 10 (8.2) | 6 (25) | 0 (0) | 16 (10.7) | 0.064 |
Non Basal | 112 (91.8) | 18 (75) | 4 (100) | 134 (89.3) | ||